| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1365-2036.2012.05217.X |
| P698 | PubMed publication ID | 22779779 |
| P50 | author | Edward V Loftus | Q56065843 |
| William Jeffery Sandborn | Q64364605 | ||
| P2093 | author name string | R H Wiesner | |
| D H Bruining | |||
| A B Mohabbat | |||
| P2860 | cites work | Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial | Q28202504 |
| Infliximab maintenance therapy for fistulizing Crohn's disease | Q28246982 | ||
| Infliximab for induction and maintenance therapy for ulcerative colitis | Q28285876 | ||
| Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee | Q33523446 | ||
| Epstein-Barr virus infection | Q34004958 | ||
| Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry | Q34077378 | ||
| Management of Crohn's disease in adults. | Q34931424 | ||
| Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis | Q35352934 | ||
| Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation | Q43628977 | ||
| Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis | Q46990369 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | TNF | Q18032037 |
| inflammation | Q101991 | ||
| inflammatory bowel diseases | Q917447 | ||
| P304 | page(s) | 569-574 | |
| P577 | publication date | 2012-07-10 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients. | |
| P478 | volume | 36 |
| Q37354812 | Anti-TNFα therapy for chronic inflammatory disease in kidney transplant recipients: Clinical outcomes |
| Q53426230 | Antitumor necrosis α treatment in primary sclerosing cholangitis associated inflammatory bowel disease after liver transplantation. |
| Q37682504 | Clinical management of inflammatory bowel disease in the organ recipient |
| Q50999859 | Complete Regression of Psoriatic Arthritis After Belatacept Conversion in a Highly HLA-Sensitized Kidney Transplant Patient. |
| Q59350071 | Efficacy and Safety of Anti-TNF-α Agents in Inflammatory Bowel Disease After Liver Transplant: A Case Series |
| Q38608954 | Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab. |
| Q59355703 | Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver |
| Q33696372 | Inflammatory bowel disease in liver transplanted patients |
| Q52601885 | Interactions between primary sclerosing cholangitis and inflammatory bowel disease: implications in the adult liver transplant setting. |
| Q46929838 | Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation |
| Q51277612 | Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis. |
| Q38225789 | Management of ulcerative colitis pre- and post-liver transplant for primary sclerosing cholangitis: two case reports and review of literature |
| Q88010964 | Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis |
| Q38107484 | Primary Sclerosing Cholangitis: Current and Future Management Strategies |
| Q41928163 | Safety and Efficacy of Biologic Agents for the Management of Inflammatory Bowel Disease After Liver Transplantation |
| Q38798001 | Safety of anti-TNF treatment in liver transplant recipients- a systematic review and meta-analysis |
| Q35750365 | Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort |
| Q61451061 | Specific Features of Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis |
| Q101454487 | The Course of Ulcerative Colitis After Pediatric Liver Transplantation for Sclerosing Cholangitis |
| Q55291155 | Tumor Necrosis Factor Alpha Inhibition for Inflammatory Bowel Disease after Liver Transplant for Primary Sclerosing Cholangitis. |
| Q54502668 | Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation. |
Search more.